CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer

Gary D Steinberg1 Department of Urology, Rush University Medical Center, Chicago, IL, USACorrespondence[email protected]

https://orcid.org/0000-0003-4469-0624

Neal D Shore2 Carolina Urologic Research Center, Grand Strand Urology, 823 82 Parkway, Myrtle Beach, SC29572, USA

Joan Palou Redorta3 Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, C. de Cartagena 340-350, 08025Barcelona, Spain

Matthew D Galsky4 The Tisch Cancer Institute, Mount Sinai, 1190 One Gustave L. Levy Place, New York, NY10029, USA

Jens Bedke5 Department of Urology, Eberhard Karls University Tübingen, Geschwister-Scholl-Platz, 72074Tübingen, Germany

Ja Hyeon Ku6 Department of Urology, Seoul National University Hospital, 101 Daehak-ro Jongno-gu, Seoul03080, Republic of Korea

Michal Kretkowski7 Clinical Research Center, Spolka z Ograniczona, Feliksa Nowowiejskiego 5, 61-731Poznań, Poland

Hailong Hu8 Institute of Urology, Second Hospital of Tianjin Medical University, 23 Pingjiang Road, Hexi District, Tianjin300211, China

Konstantin Penkov9 Private Medical Institution Euromedservice, Suvorovskiy Prospekt, 60, St Petersburg, Russia

Jennifer J Vermette10 Pfizer Oncology, Pfizer, 1 Portland Street, Cambridge, MA02139, USA

Jamal C Tarazi11 Pfizer Oncology, Pfizer, 10646 Science Center Drive, San Diego, CA92121, USA

Alison E Randall12 Pfizer Oncology, Pfizer, 235 East 42nd Street, New York, NY10017, USA

Kristen J Pierce13 Pfizer Oncology, Pfizer, 280 Shennecossett Road, Groton, CT06340, USA

Daniel Saltzstein14 Division of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX78229, USA

Thomas B Powles15 Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 5PZ, UK

show all

CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer

Supplementary document

Supplementary document

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer

Supplementary document

Supplementary document

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date